Novocure Inc.

Novocure Inc., a foreign-owned medical device manufacturer, operates as a prime contractor selling Optune Tumor Treating Fields (TTFields) cancer therapy systems and transducer components to the Department of Veterans Affairs through the GSA Federal Supply Schedule (FSS-65-II-A) for Medical Equipment and Supplies, competing full-and-open with no set-aside designations. The company delivers non-invasive oncology devices and related support services directly to VA medical centers nationwide, with no subcontractor involvement, ensuring proprietary control over its cancer treatment technologies.

Novocure's federal customer footprint is concentrated almost entirely within the VA's Veterans Health Administration. The source covers 1,114 prime awards across 19 distinct agencies, but the VA accounts for virtually all activity. Within the VA, the top five Veterans Integrated Service Networks by award count—VISN 10 (117 awards, $4.4 million), VISN 23 (100 awards, $5.4 million), VISN 1 and VISN 7 (90 awards each, $2.3 million and $3.1 million respectively), and VISN 20 (88 awards, $3.6 million)—collectively represent 44% of the award footprint. When ranked by potential value, VISN 12 dominates with just 53 awards carrying $31 million in combined potential value, signaling a concentration in larger-dollar delivery orders. VISN 23 and VISN 10 rank second and third by dollars. The top five VISNs by potential value account for 65% of the combined $73.6 million portfolio, indicating high customer concentration risk.

Novocure holds a single parent vehicle: the Medical Equipment and Supplies FSS-65-II-A contract, a $28.85 million multiple-award schedule established November 1, 2022, and extending through October 31, 2027. Against this vehicle, 602 task orders have been issued across multiple VISNs, generating $24.1 million in combined potential value. Individual delivery orders typically range from approximately $16,600 to $99,500 and are structured as firm fixed-price contracts. The FSS vehicle enables rapid, streamlined procurement across the VA's integrated service network system. Place of performance is predominantly Portsmouth, New Hampshire (the company's headquarters location), with secondary performances distributed across various VA medical facility locations nationwide, including facilities in Minnesota, Texas, California, Pennsylvania, and other states where veteran populations require cancer treatment capabilities.

Recent activity has remained steady year over year. The source reflects 132 awards in 2026 (through mid-July), 203 in 2025, 229 in 2024, 211 in 2023, and 161 in 2022—demonstrating sustained federal demand and no significant decline. Seventy-two awards with completion dates in the next twenty-four months carry combined potential value of $3.8 million and face recompete risk if Novocure's FSS contract renews or if the VA pursues alternative cancer therapy vendors. The category concentration is heavily concentrated in NAICS 334517 (Electromedical and Electrotherapeutic Apparatus Manufacturing), which accounts for 711 of the 1,114 awards, and PSC Medical And Surgical Instruments, Equipment, And Supplies (1,007 awards).

Novocure's award portfolio reflects its position as the sole-source provider of Tumor Treating Fields technology to the VA. Representative work includes recurring delivery orders for Optune Plus transducers, transducer rental arrangements (typically 1-month to 6-month terms at $16,600 to $99,500 per order), and prosthetics/surgical implant classifications related to cancer treatment device components. Awards are frequently clinician-prescribed in accordance with 38 USC 8123, indicating direct patient-care integration. The company manufactures and supplies non-invasive medical devices with FDA approval for glioblastoma and mesothelioma treatment, with no competitive set-asides applied across the footprint—a reflection of Novocure's proprietary technology posture and sole-source market position within the federal healthcare procurement system.